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Introduction: Esophageal squamous cell carcinoma (ESCC) is the
6th most common fatal cancer in men and 9th in women in the world
and the 5th leading cause of cancer in Iran. A high frequency of ESCC
in northeastern Iran has been reported. BRCA2 may play an important
role in ESCC carcinogenesis as indicated from various studies in Iran,
India and China. Mutational analysis of BRCA2 in several familial ESCC
pedigrees with affected ESCC individuals was performed.
Materials and methods: We screened patients for BRCA2
mutations in germ line DNA by whole gene sequencing. Some known
BRCA2 mutations and a novel splice variant, c.426-2A>G were found.
Novel mutation tracking ruled out SNP in 100 chromosomes of
healthy individuals. The related family members, 60 sporadic and 12
familial ESCC were negative for this new mutation.
Results: The novel splice variant mutation was found in two
affected ESCC sisters, 54 yr and 48 yr old, and their sons and
daughters, two brothers and two nephews. Sequencing of BRCA2
cDNA, exons 4 to 7, revealed that c. 426-2A>G mutation lead to exon
5 skipping in splicing process.
Conclusion: We conclude that germ line mutation in BRCA2 in
ESCC patients may play a role in genetic susceptibility to familial ESCC.
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Introduction: Previous studies showed that autophagy protects
some cancerous cells against anticancerous effects of some drugs by
blocking the apoptotic pathway. By contrast, other cancerous cells
undergo autophagic cell death (programmed cell death type II) after
cancer therapies. In parallel with world-wide investigations for
finding some potent anti-tumor drugs against those breast cancer
cells originated from epithelial tissues, we choose sulfabenzamide for
assessing its anti-cancerous activity on T-47D cell line.
Methods: Our results obtained from flow cytometry, fluorescent
microscopy and DNA laddering investigations, confirmed that the
percentage of apoptosis, necrosis and cell cycle arrest could not
explain the observed 50 percent reduction of the cell number when
the cells treated with 10.8 mM sulfabenzamide (LC50). These findings
motivated us to investigate expression level of some genes involved
in autophagy pathway for example ATG5, DRAM, DAPK, mTOR, AKT
and so on with real time RT-PCR.
Results: Sulfabenzamide induced overexpression of the autopha-
gic regulator genes for example PTEN in parallel with decreasing of
AKT1 transcripts showed that the possible repression of the cell
surviving pathway (AKT pathway) has occurred. Interestingly, DAPK
(positive regulator of autophagy) had been expressed in the treated
cells while it has not had any expression in the untreated cells.
Moreover, about 10 times increasing of DRAM transcripts in the
treated cells showed that p53/DRAM pathway has been started
causing autophagic death in this cell line.
Conclusion: This study is the first one explaining the anticancer
effects of sulfabenzamide on the human breast cancer cells through
autophagic cell death.
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Introduction: Tumors of digestive tract are in the third place
between men and women and have the lowest life rate in all solid
tumor cases. Every year tumors of digestive tract are revealed in
about 61,000 persons who are convicted to death. The reason is that
in most patients disease is revealed in old stages. Diagnostics is set on
the basis of endoscopic ultrasound investigation, endoscopic retro-
grade cholangiopancreatoscopy and histological or cytological deci-
sion of punctional biopsy. The aim of the study is to make
comparative analysis of CA 19-9, CA 242 and CEA tumor markers.
Methods: The objective of the study was to analyze the diagnostic
value of CA 19-9, CA 242 and CEA tumor markers. The ELISA method
was used to quantify the level of proteins of interest.
Results: CA 242 marker was the highest in stomach carcinoma
samples (2 times higher than CA 19-9). The level of CA 19-9
glycoprotein was in average 18 and 7 times higher than CA 242 and
CEA proteins in pancreas and bile duct carcinoma respectively. CEA
was equally high in all groups but the highest level was detected in
bile duct carcinoma and intestine carcinoma.
Conclusion: Although there is some level of specificity for
each marker and corresponding cancer, anyway the simultaneous
detection of all three markers together may increase its diagnostic
value.
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Introduction: Cupper containing amine oxidase (Cu-AO) cata-
lyzes the deamination of primary amines to corresponding aldehydes
in the presence of oxygen with the subsequent release of ammonia
and hydrogen peroxide. Cu-AO also is known as soluble vascular
adhesion molecule-1 (sVAP-1). It has been shown that the serum
level of Cu-AO changes in various cancers. Literature review showed
that there was no information on Cu-AO serum concentration among
Iranians as well as in gastric cancer patients. The present study was
conducted with two major aims 1) determination of Cu-AO
concentration in healthy people; 2) to investigate the changes of
the enzyme in gastric patients compared to control.
Material and method: This investigation as a case–control study
included 200 healthy and GC patient volunteers referred to Aras
Clinic in Imam Khomeini Hospital. Blood samples were collected and
serum was separated and stored at−70 °C until ELISA examinations.
Questionnaires were distributed and filled out by both patients and
healthy people.
Results and conclusion: Present investigation showed that there
is no significant change in serum level of Cu-AO in regard to sex, age,
smoking and BMI. The serum level of Cu-AO in healthy subjects was
higher than values reported in other countries. Whether these finding
would open new sights into etiology of high incidence of GC in
Ardabil province needs further investigations. Cu-AO levels in serum
show a significant decrease in GC patients in relative to controls, this
decline in Cu-AO might have been used as a biomarker for gastric
cancer diagnosis.
Keywords: SSAO, sVAP, biomarker, gastric cancer
doi:10.1016/j.clinbiochem.2011.08.521
Poster—[A-10-1199-1]
The evaluation of FOXP3 and GITR gene expression in ATL patients
before and after treatment with triple arsenic regimen using real
time PCR TaqMan method
Valizadeh Narges, Rahimi Hossein, Shirdel Abbas, Farid Hosseini Reza,
Rafatpanah Houshangnah, Rezaee Abdlrahim
Inflamation and Inflamatory Disease Research Center, Mashhad, Iran
E-mail addresses: valizadehn1@mums.ac.ir (V. Narges),
hrafatpanah@hotmail.com (R. Houshangnah),
rezaeesa@mums.ac.ir (R. Abdlrahim)
Introduction: HTLV-1 was recognized as the etiologic agent of the
syndrome of adult Tcell leukemia (ATL) which may infect T regulatory
cell. FOXp3 and GITR are the main markers for T regulatory cell.
Therefore, in the present study FOXp3 and GITR genes expression
were measured in ATL patients before and after treatment.
Materials and method: 12 (43%) and 16 (57%) of the ATL patients
were female and male, respectively. Twenty eight ATL patients, 10
HTLV-1 healthy carriers and 10 healthy controls were included in this
study. All ATL patients had serologic evidence of HTLV-I infection by
enzyme-linked immunosorbent assay (ELISA) that were confirmed
polymerase chain reaction (PCR). Peripheral mononuclear blood cells
(PBMCs) were obtained from ATL patients at the onset of their
disease before and after 30 days of treatment with Zidovidune (300–
900 mg/day), Interferon alpha (INF-α, 3–5 million IU/day and sub-
cutaneously) Arsenic trioxide: 1 cycle=10 mg, 5 days per week. After
one month of treatment a second blood sample was taken and FOXP3
and GITR genes expression were evaluated in both samples using a
TaqMan Real time RT-PCR which designed in our lab.
Results: The levels of FOXP3 and GITR mRNA levels in ATL patients
after one month treatment were significantly decreased (p<0.001).
Therefore, this kindof treatmentmay reduce thenumberand the function
of Treg result in potentiating of immune response to malignant cells.
Conclusion: In conclusion, treatment of chronic ATL with arsenic,
interferon-alpha and zidovudine is feasible and exhibits an impressive
response with moderate toxicity.
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Introduction: Human breast is composed of two components:
Specialized epithelium and Stroma. Epithelium consists of two cell
types. One is low, flattened myoepithelial layer, also called basal cells.
Second layer is of epithelial cells which line the lumen of ducts and
lobules, also called luminal cells. Stroma composed of fibrous and
adipose tissue. The structure and function of normal breast require
complex interactions between luminal cells, myoepithelial cells and
stromal cells. The normal process of new duct lobule formation via
increased proliferation, escape from growth inhibition, angiogenesis
and during carcinogenesis stromal invasion can be opted by abnormal
epithelial and stromal cells. Loss of normal function of cells can occur
with:-Age, mutations or genetic changes in DNA (Hereditary cancer),
Hormonal stimulation and proliferation (Sporadic cancer). Circulat-
ing tumor cells are cells that have detached from primary tumor and
entered the peripheral circulation. Diagnostic Modalities. Early
detection of breast cancer is vital to reducing the morbidity and
mortality associated with this disease and triple test was used for the
accuracy of its diagnosis like mammography, self assessment, FNAC
and Biopsy Recent advances in diagnostic modalities. Molecular
techniques have also been used to refine the classification of special
type cancers. For example, using the combination of immunohisto-
chemistry to assess protein expression and gene expression profiling
of breast carcinom.Immunohistochemistry using six common anti-
bodies (ER, PR, HER2, CK5/6, EGFR, and Ki67) (7-9) can be used as a
surrogate for gene expression profiling to classify tumors as luminal
A, luminal B, HER2 and basal-like types. Luminal A cancers are ER+
and/or PR+, HER2- and have a Ki67 labeling index <14%. Luminal B
tumors are either ER+ and/or PR+and HER2+ (the luminal-HER2
subtype) or ER+ and/or PR+ with a Ki67 labeling index >14%. HER2
tumors are ER-, PR- and HER2+. The basal-like cancers are most
commonly ER-, PR-, HER2- and show expression of CK5/6 and/or
EGFR. Recent studies using Gene expression profile shows a
considerable heterogeneity in both above mentioned groups. High
throughput technologies such as expression profiling has recently
introduced new taxonomy of IBC Treatment of the breast cancer in
the light of new diagnostic modalities: The paradigms of clinical
research in breast cancer are changing. Breast cancer is now
recognized as a collection of quite different malignancies, with very
different behaviors, genetic profiles and responses to therapy. The
overarching mission of the Consortium is to lessen the burden of
breast cancer by using a collaborative and multidisciplinary approach
to improve the understanding of breast cancer biology and test new
therapeutic strategies in Pakistan. On the basis of new concept the
three main treatment groups are emerged, ER/PR positive and HER 2
negative (on usual Hormonal therapy), ER/PR negative but HER2
(Herceptin) and Triple negative to test a new way of chemotherapy
that are not amenable to therapy with drugs that target the estrogen
receptor or the HER2 receptor.We will categories the patients in three
groups. ER/PR positive (on usual therapy), ER/PR negative but HER2
AbstractsS210
